Smartwatch inertial sensors continuously monitor real-world motor fluctuations in Parkinson's disease

被引：131

作者：

Powers, Rob ^{[1
]}

Etezadi-Amoli, Maryam ^{[1
]}

Arnold, Edith M. ^{[1
]}

Kianian, Sara ^{[1
,2
]}

Mance, Irida ^{[1
]}

Gibiansky, Maxsim ^{[1
]}

Trietsch, Dan ^{[1
]}

Alvarado, Alexander Singh ^{[1
]}

Kretlow, James D. ^{[1
]}

Herrington, Todd M. ^{[3
,4
]}

Brillman, Salima ^{[5
]}

Huang, Nengchun ^{[6
]}

Lin, Peter T. ^{[6
]}

Pham, Hung A. ^{[1
]}

Ullal, Adeeti, V ^{[1
]}

机构：

[1] Apple Inc, Cupertino, CA 95014 USA

[2] SUNY Stony Brook, Renaissance Sch Med, Stony Brook, NY 11794 USA

[3] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA

[4] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA

[5] Parkinsons Dis & Movement Ctr Silicon Valley, Menlo Pk, CA 94025 USA

[6] Silicon Valley Parkinsons Ctr, Los Gatos, CA 95032 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2021年 / 13卷 / 579期

关键词：

MOVEMENT-DISORDER SOCIETY; QUALITY-OF-LIFE; RATING-SCALE; LEVODOPA; TREMOR; SYMPTOMS; HEALTH; DYSKINESIAS; RELIABILITY; DISPARITIES;

D O I：

10.1126/scitranslmed.abd7865

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Longitudinal, remote monitoring of motor symptoms in Parkinson's disease (PD) could enable more precise treatment decisions. We developed the Motor fluctuations Monitor for Parkinson's Disease (MM4PD), an ambulatory monitoring system that used smartwatch inertial sensors to continuously track fluctuations in resting tremor and dyskinesia. We designed and validated MM4PD in 343 participants with PD, including a longitudinal study of up to 6 months in a 225-subject cohort. MM4PD measurements correlated to clinical evaluations of tremor severity (p = 0.80) and mapped to expert ratings of dyskinesia presence (P < 0.001) during in-clinic tasks. MM4PD captured symptom changes in response to treatment that matched the clinician's expectations in 94% of evaluated subjects. In the remaining 6% of cases, symptom data from MM4PD identified opportunities to make improvements in pharmacologic strategy. These results demonstrate the promise of MM4PD as a tool to support patient-clinician communication, medication titration, and clinical trial design.

引用

页数：11

共 86 条

[1] Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely [J].